Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.

@article{Jnsson1991PhaseIS,
  title={Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.},
  author={Per J{\"o}nsson and Martin Malmberg and Lars Bergljung and Christian Ingvar and Mats Henrik Ericsson and Stefan Ryd{\'e}n and Ingrid Holmqvist Nilsson and I J Terje},
  journal={Anticancer research},
  year={1991},
  volume={11 2},
  pages={
          873-5
        }
}
Thirty-five (34 evaluable) consecutive postmenopausal women with estrogen receptor positive (greater than or equal to 10 fmol/mg) or unknown advanced breast cancer were treated with high dose toremifene in a phase II study. All patients had progressed during prior adjuvant or palliativ antiestrogen treatment. The dose of toremifene was 240 mg per day. No complete or partial responders were registered. Nine patients (26%) were considered to have stable disease (NC). The time to progression for… CONTINUE READING